Dr Peter Fellner was appointed Chairman in May 2009, having served as a director since November 2005. He is also Chairman of Vernalis plc, Optos plc, Biotie Therapies Corp. and Vice Chairman of Astex Pharmaceuticals, Inc. In addition he serves as a director of the global biopharmaceutical company UCB SA. He is a member of the Novo A/S Advisory Group. Dr Fellner previously served as Chairman of Celltech Group plc from 2003 to July 2004, having been CEO from 1990 onwards. Before joining Celltech he was CEO of Roche UK from 1986 to 1990. More recently he served as Chairman of Acambis plc from 2006 until 2008, and of Premier Research Group plc from 2007 to 2008 and also served as a director of QinetiQ Group plc and Evotec AG. Peter is Chairman of the Nomination Committee.Close
Jonathan Glenn was appointed Chief Executive in December 2007 and before that had been Group Finance Director since September 2006. Prior to joining Consort Medical plc, Jonathan was Global Head of Finance at Celltech Group plc and later Chief Financial Officer of Akubio Ltd, a Cambridge based developer of instrumentation for the life sciences industry. He is a member of the Institute of Chartered Accountants in England and Wales. Jonathan is a member of the Nomination Committee.Close
Richard Cotton was appointed Group Finance Director in June 2012. He is a Chartered Management Accountant. From 2008 to 2011 he was Group Finance Director of Vitec Group plc, from 2005 to 2008 Group Finance Director at Wagon, and from 2001 to 2005 Group Finance Director of McLeod Russell plc.Close
Steve Crummett was appointed as a non executive director in June 2012. Steve is currently the Finance Director of Morgan Sindall Group plc. Previously Steve was Group Finance Director of Filtrona plc from 2008 to 2012 and from 2003 to 2006, Steve was Group Director, Mergers & Acquisitions of the FTSE 100 company Exel plc. Steve qualified as a Chartered Accountant with Arthur Andersen. Steve is Chairman of the Audit Committee and a member of the Remuneration Committee and the Nomination Committee.Close
Ian Nicholson was appointed as a non executive director in June 2012. He is also Chairman of Bioventix Ltd, a diagnostics company, Chief Executive Officer of F2G Ltd, a UK-based antifungal drug discovery and development company,a Non-executive Director of Symphogen A/S, an antibody therapeutics company and Clinigen Group plc a specialty pharmaceuticals and services business, and also an Operating Partner at Advent Life Sciences. From 2004 to 2012 Ian was Chief Executive of Chroma Therapeutics Limited, a drug discovery and development company and from 2000 to 2004 Ian was Senior Vice President, Business Development at Celltech Group plc, then the UK's largest biotechnology company. He has extensive experience in licensing, mergers and acquisitions, and market development in the UK, Europe and the US. Ian is Chair of the Corporate Responsibility Committee and a member of the Audit Committee and Nomination Committee.Close
Dr William Jenkins was appointed as a non-executive director in May 2009 and is Principal of William Jenkins Pharma Consulting. He has been advising a wide range of pharma and biotech companies and investment and venture capital firms in the healthcare sector since 1999. Formerly head of Worldwide Clinical and Regulatory Affairs for Novartis Pharma AG and has held similar positions with Ciba Geigy AG and Glaxo. He is also a director Vaximm AG. William is the Senior Independent Director, Chair of the Remuneration Committee and a member of the Nomination Committee.Close
Dr Lynn Drummond was appointed as a non-executive director on 9 February 2011. Lynn is the non executive Chairman of InFirst Healthcare Limited, a consumer healthcare company. She is also a non-executive director of Allocate Software plc, the leading workforce optimisation and compliance software applications provider for organisations with large, multi-skilled workforces and Shield Holdings AG. a speciality mineral medicines pharmaceutical company. Lynn is a Fellow of the Royal Society of Edinburgh and the Royal Society of Chemistry. She was previously a Managing Director at Rothschild and her focus was on advising clients within the healthcare sector. Prior to this she worked in the Cabinet Office in London as Private Secretary to the Chief Scientific Advisor. Lynn is a member of the Audit Committee and the Nomination Committee.